Identification

Name
Efonidipine
Accession Number
DB09235
Type
Small Molecule
Groups
Approved, Investigational
Description

Efonidipine (INN) is a dihydropyridine calcium channel blocker marketed by Shionogi & Co. of Japan. It was launched in 1995, under the brand name Landel. The drug blocks both T-type and L-type calcium channels [1, 2]. It has also been studied in atherosclerosis and acute renal failure [2]. This drug is also known as NZ-105, and several studies have been done on its pharmacokinetics in animals [13].

Structure
Thumb
Synonyms
Not Available
External IDs
NZ-105
Product Ingredients
IngredientUNIICASInChI Key
Efonidipine hydrochloride3BR983K69O111011-53-1OXVTXPCIJDYQIS-UHFFFAOYSA-N
International/Other Brands
Landel (Shionogi & Co.) / NZ-105 / Selefodipine
Categories
UNII
40ZTP2T37Q
CAS number
111011-63-3
Weight
Average: 631.666
Monoisotopic: 631.244737574
Chemical Formula
C34H38N3O7P
InChI Key
NSVFSAJIGAJDMR-UHFFFAOYSA-N
InChI
InChI=1S/C34H38N3O7P/c1-24-30(33(38)42-19-18-36(28-15-9-6-10-16-28)21-26-12-7-5-8-13-26)31(27-14-11-17-29(20-27)37(39)40)32(25(2)35-24)45(41)43-22-34(3,4)23-44-45/h5-17,20,31,35H,18-19,21-23H2,1-4H3
IUPAC Name
2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxo-1,3,2λ⁵-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate
SMILES
CC1=C(C(C2=CC=CC(=C2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(CC1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of hypertension.

Pharmacodynamics

Dihydropyridines (DHPs), act mainly on L-type calcium channels, essentially causing reflex tachycardia, which negatively affects cardiac function. This leads to a decrease in blood pressure and an increase in heart rate. Efonidipine acts on both L-type and T-type calcium channels. Because inhibition of T-type calcium channels in the sinoatrial (SA node) node attenuate reflex tachycardia, this drug favorably affects cardiac pacing. The effect of efonidipine on heart rate deserves special recognition with regard to reflex tachycardia, due to its unique effects in relation to other drugs in its class [5].

Mechanism of action

This drug inhibits the L-type and T-type calcium channels, thereby leading to vasodilation and decreased automaticity of the heart. Efonidipine has a negative chronotropic effect. Acting on SA node cells by inhibiting T-type calcium channel activity, Efonidipine prolongs the late phase-4 depolarization of the sinoatrial node action potential, decreasing heart rate. This is associated with decreased myocardial oxygen demand and increases of blood flow to the coronary arteries and thereby attenuates myocardial ischemia. Efonidipine increases glomerular filtration rate (GFR) without increasing intra-glomerular pressure and filtration fraction [1, 3, 4] . This prevents hypertension-induced renal damage. Efonidipine enhances sodium excretion from the kidneys by suppressing aldosterone synthesis and secretion from the adrenal glands. Aldosterone-induced renal parenchymal fibrosis is said to be suppressed by efonidipine [4]. L-type calcium channel blockers, such as efonidipine, preferentially dilate afferent arterioles in the kidney, whereas both L-/T-type and L-/N-type calcium channel blockers potently dilate both afferent and efferent arterioles. The distinct actions of calcium channel blockers on the renal microcirculation are demonstrated by changes in glomerular capillary pressure and subsequent renal injury: L-type calcium channel blockers favor an increase in glomerular capillary pressure, whereas L-/T-type and L-/N-type CCBs alleviate glomerular hypertension. This supports the theory that L-Type/T-type calcium channel blockers may be of benefit in renal hypertension [4]. Efonidipine is a long-acting medication due to a low dissociation constant [11].

Recent studies suggest that efonidipine reduces plasma aldosterone levels in patients on regular hemodialysis, which is of additional benefit to the cardiovascular protection by antihypertensive therapy with efonidipine in patients with end-stage renal disease [5].

TargetActionsOrganism
UVoltage-dependent T-type calcium channel subunit alpha-1I
antagonist
Human
UVoltage-dependent L-type calcium channel subunit alpha-1CNot AvailableHuman
Absorption

The metabolism of efonidipine was studied in rats. The absorption ratio of radioactivity estimated from the sum of biliary and urinary excretions was found to be approximately 62% [14]. The radioactivity was high in the gastrointestinal tract and liver, followed by the adrenal glands [14], suggesting high rates of metabolism in these regions.

The unchanged drug in the plasma accounted for 47.7% of radioactivity at 2hr after ingestion, demonstrating a lower first-pass effect in comparison with other drugs in the same class. In plasma, major metabolites of NZ-105 were: N-debenzylated compound (DBZ), N-dephenylated compound (DPH), oxidative deaminated compound (AL), AL-corresponding pyridine compound (ALP), unknown metabolite M-1 and M-25. NZ-105 was metabolized by N-debenzylation, N-dephenylation, oxidative deamination, ester hydrolysis and oxidation of 1, 4-dihydropyridine ring to its corresponding pyridine [14].

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

It has been suggested that efonidipine is less likely to be subject to the first-pass than other members of its drug class, and and that its dihydropyridine ring is oxidized primarily after metabolism of the side chain [8]. Efonidipine is highly lipophilic and this allows for its entry into the phospholipid-rich cell membrane and reach the dihydropyridine binding site of the calcium channel targets [10].

Efonidipine is mainly metabolized in the liver. Its metabolites are N-dephenylated Efonidipine (DPH), deaminated efonidipine (AL) and N-debenzylated Efonidipine (DBZ). DBZ and DPH exhibit act as calcium antagonists. In one study, the vasodilating capabilities of DBZ and DPH were about two-thirds and one-third respectively than that of the unmetabolized drug. Research suggests that the majority of the pharmacological effect after oral dosing of efonidipine hydrochloride is due to unchanged drug and its metabolites play little role in its therapeutic effect.

In a study of six healthy volunteers, no significant amount of unchanged drug was excreted in urine. The urine samples collected for 24 h after oral efonidipine administration, 1.1% of the dose was excreted as deaminated-efonidipine, and 0.5% as a pyridine analogue of deaminated-efonidipine [14].

Route of elimination

Efonidipine is also referred to as NZ-105 [13] and has been found to be mainly eliminated by the biliary system [14].

Half life

Peak plasma concentration is achieved at about 1.5 to 3.67 hours after ingestion. Half-life is approximately 4 hours [12].

Clearance
Not Available
Toxicity

Ld50: >5 g/kg in rats, orally [6, 15]. The most common adverse effects are hot flushes, facial flushing, and headache. Elevation in serum total cholesterol, ALT (SGPT), AST (SGOT) and BUN may also occur. Frequent urination, pedal edema, increased triglycerides have been found to occur in less than 0.1% of patients [16, 15].

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Efonidipine.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Efonidipine.Vet Approved
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Efonidipine.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
AcemetacinThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Efonidipine.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Efonidipine is combined with Aldesleukin.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Efonidipine.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Efonidipine.Approved, Investigational
AliskirenAliskiren may increase the hypotensive activities of Efonidipine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Efonidipine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Efonidipine.Illicit
AlprenololAlprenolol may increase the hypotensive activities of Efonidipine.Approved, Withdrawn
AmbrisentanEfonidipine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineEfonidipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Efonidipine is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Efonidipine.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Efonidipine.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Efonidipine.Approved
AmobarbitalThe metabolism of Efonidipine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Efonidipine.Approved, Investigational
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Efonidipine.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Efonidipine.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Efonidipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Efonidipine is combined with Amyl Nitrite.Approved
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Efonidipine.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Efonidipine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Efonidipine.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Efonidipine.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Efonidipine.Approved, Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Efonidipine.Approved
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Efonidipine.Approved
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Efonidipine.Approved, Investigational, Withdrawn
AtenololAtenolol may increase the hypotensive activities of Efonidipine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Efonidipine is combined with Atorvastatin.Approved
AvanafilAvanafil may increase the antihypertensive activities of Efonidipine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Efonidipine is combined with Azilsartan medoxomil.Approved, Investigational
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Efonidipine.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Efonidipine.Experimental
BarbitalThe metabolism of Efonidipine can be increased when combined with Barbital.Illicit
BarnidipineEfonidipine may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Efonidipine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Efonidipine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Efonidipine.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Efonidipine.Approved, Investigational
BepridilBepridil may increase the hypotensive activities of Efonidipine.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Efonidipine.Approved
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Efonidipine.Approved
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Efonidipine.Experimental, Illicit, Withdrawn
BietaserpineBietaserpine may increase the hypotensive activities of Efonidipine.Experimental
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Efonidipine.Approved, Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Efonidipine.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Efonidipine.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Efonidipine.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Efonidipine.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Efonidipine.Approved
BQ-123Efonidipine may increase the hypotensive activities of BQ-123.Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Efonidipine.Experimental
BretyliumBretylium may increase the hypotensive activities of Efonidipine.Approved
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Efonidipine.Approved, Investigational
BrimonidineBrimonidine may increase the antihypertensive activities of Efonidipine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Efonidipine.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Efonidipine.Approved, Investigational
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Efonidipine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Efonidipine is combined with Bumetanide.Approved
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Efonidipine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Efonidipine.Approved, Investigational
BupranololBupranolol may increase the hypotensive activities of Efonidipine.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Efonidipine.Approved, Illicit, Investigational, Vet Approved
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Efonidipine.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Efonidipine.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Efonidipine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Efonidipine.Approved
CadralazineCadralazine may increase the hypotensive activities of Efonidipine.Experimental
CafedrineEfonidipine may increase the hypotensive activities of Cafedrine.Investigational
Calcium AcetateThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium Phosphate.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Efonidipine is combined with Canagliflozin.Approved
CandesartanEfonidipine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilThe risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Efonidipine.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Efonidipine.Withdrawn
CandoxatrilCandoxatril may increase the hypotensive activities of Efonidipine.Experimental
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Efonidipine.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Efonidipine.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Efonidipine.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Efonidipine.Illicit, Investigational, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Efonidipine.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Efonidipine.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Efonidipine.Approved, Investigational
CaseinThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Efonidipine.Approved
CeliprololCeliprolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Efonidipine.Approved, Withdrawn
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Efonidipine.Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Efonidipine.Approved, Vet Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Efonidipine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Efonidipine.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Efonidipine.Approved
CicletanineEfonidipine may increase the hypotensive activities of Cicletanine.Investigational
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Efonidipine.Approved, Investigational
CilazaprilCilazapril may increase the hypotensive activities of Efonidipine.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Efonidipine.Approved, Investigational
CimetidineThe serum concentration of Efonidipine can be increased when it is combined with Cimetidine.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Efonidipine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Efonidipine.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Efonidipine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Efonidipine.Approved
CloranololEfonidipine may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe therapeutic efficacy of Clotrimazole can be increased when used in combination with Efonidipine.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Efonidipine.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Efonidipine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Efonidipine.Approved, Investigational
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Efonidipine.Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Efonidipine.Approved
CyclopenthiazideEfonidipine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe therapeutic efficacy of Cyclosporine can be increased when used in combination with Efonidipine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Efonidipine.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Efonidipine is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Efonidipine.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Efonidipine.Approved, Investigational
DelaprilEfonidipine may increase the hypotensive activities of Delapril.Investigational
DeserpidineEfonidipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Efonidipine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineThe risk or severity of hypotension can be increased when Dextroamphetamine is combined with Efonidipine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Efonidipine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Efonidipine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Efonidipine.Approved, Investigational
DiazoxideDiazoxide may increase the hypotensive activities of Efonidipine.Approved
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Efonidipine.Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Efonidipine is combined with Diclofenamide.Approved, Investigational
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of Efonidipine.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Efonidipine.Approved, Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Efonidipine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Efonidipine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Efonidipine.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Efonidipine.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Efonidipine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Efonidipine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Efonidipine.Experimental, Illicit
DiltiazemDiltiazem may increase the hypotensive activities of Efonidipine.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Efonidipine is combined with Dinutuximab.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Efonidipine.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Efonidipine is combined with Dipyridamole.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Efonidipine.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Efonidipine.Approved
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Efonidipine.Approved, Investigational
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Efonidipine.Experimental
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Efonidipine.Approved
DroperidolThe risk or severity of hypotension can be increased when Droperidol is combined with Efonidipine.Approved, Vet Approved
DuloxetineEfonidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Efonidipine.Approved
EfavirenzThe serum concentration of Efonidipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Efonidipine is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Efonidipine.Approved, Vet Approved
EnalaprilatEfonidipine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Efonidipine.Experimental
EpanololEfonidipine may increase the hypotensive activities of Epanolol.Experimental
EpinephrineThe risk or severity of hypotension can be increased when Epinephrine is combined with Efonidipine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Efonidipine is combined with Eplerenone.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Efonidipine.Approved
EprosartanEprosartan may increase the hypotensive activities of Efonidipine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Efonidipine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Efonidipine.Approved
EscitalopramThe risk or severity of hypotension can be increased when Escitalopram is combined with Efonidipine.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Efonidipine is combined with Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Efonidipine is combined with Etacrynic acid.Approved, Investigational
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Efonidipine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Efonidipine.Illicit, Vet Approved
FelodipineFelodipine may increase the hypotensive activities of Efonidipine.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Efonidipine.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Efonidipine.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Efonidipine.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Efonidipine.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Efonidipine is combined with Fimasartan.Approved, Investigational
FluconazoleThe therapeutic efficacy of Fluconazole can be increased when used in combination with Efonidipine.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Efonidipine.Approved, Investigational
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Efonidipine.Approved, Investigational, Withdrawn
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Efonidipine.Experimental
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Efonidipine.Approved
FosinoprilFosinopril may increase the hypotensive activities of Efonidipine.Approved
FostamatinibFostamatinib may increase the antihypertensive activities of Efonidipine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Efonidipine.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Efonidipine is combined with Furosemide.Approved, Vet Approved
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Efonidipine.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Efonidipine.Approved, Investigational, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Efonidipine.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Efonidipine.Approved
GuanazodineEfonidipine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Efonidipine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Efonidipine.Approved, Investigational
GuanoclorEfonidipine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzEfonidipine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanEfonidipine may increase the hypotensive activities of Guanoxan.Experimental
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Efonidipine.Experimental
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Efonidipine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Efonidipine is combined with Halothane.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Efonidipine.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Efonidipine.Approved, Illicit, Investigational
HexamethoniumHexamethonium may increase the hypotensive activities of Efonidipine.Experimental
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Efonidipine.Approved, Investigational
HexobarbitalThe metabolism of Efonidipine can be increased when combined with Hexobarbital.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Efonidipine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Efonidipine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Efonidipine.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Efonidipine.Approved, Illicit
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Efonidipine.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Efonidipine.Approved, Illicit
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Efonidipine.Approved
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Efonidipine.Approved
IloprostThe risk or severity of adverse effects can be increased when Efonidipine is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Efonidipine is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Imipramine.Approved
IndapamideIndapamide may increase the hypotensive activities of Efonidipine.Approved
IndenololIndenolol may increase the hypotensive activities of Efonidipine.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Efonidipine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Efonidipine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Efonidipine.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Efonidipine.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Efonidipine.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Efonidipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Efonidipine is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Efonidipine is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Efonidipine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Efonidipine.Approved, Investigational
ItraconazoleThe therapeutic efficacy of Itraconazole can be increased when used in combination with Efonidipine.Approved, Investigational
KetanserinKetanserin may increase the hypotensive activities of Efonidipine.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Efonidipine.Approved, Investigational
KetoconazoleThe therapeutic efficacy of Ketoconazole can be increased when used in combination with Efonidipine.Approved, Investigational
LabetalolLabetalol may increase the hypotensive activities of Efonidipine.Approved
LacidipineEfonidipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Efonidipine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Efonidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Efonidipine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Levobupivacaine.Approved, Investigational
LevodopaEfonidipine may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Efonidipine.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Efonidipine.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Efonidipine is combined with Levosimendan.Approved, Investigational
LinsidomineEfonidipine may increase the hypotensive activities of Linsidomine.Experimental
LisdexamfetamineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Efonidipine.Approved, Investigational
LisinoprilLisinopril may increase the hypotensive activities of Efonidipine.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Efonidipine.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Efonidipine.Illicit
LofexidineLofexidine may increase the hypotensive activities of Efonidipine.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Efonidipine.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Efonidipine.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Efonidipine.Illicit, Investigational, Withdrawn
MacitentanEfonidipine may increase the hypotensive activities of Macitentan.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Efonidipine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Efonidipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Efonidipine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Efonidipine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineEfonidipine may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Efonidipine is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Efonidipine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Efonidipine.Approved, Investigational
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Efonidipine.Experimental
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Efonidipine.Experimental
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Efonidipine.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Efonidipine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Efonidipine.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Efonidipine is combined with Methazolamide.Approved
MethohexitalThe metabolism of Efonidipine can be increased when combined with Methohexital.Approved
MethoserpidineEfonidipine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Efonidipine.Approved, Investigational
MethyclothiazideThe risk or severity of adverse effects can be increased when Efonidipine is combined with Methyclothiazide.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Efonidipine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Efonidipine.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Efonidipine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Efonidipine.Approved, Investigational
MethylphenobarbitalThe metabolism of Efonidipine can be increased when combined with Methylphenobarbital.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Efonidipine.Approved
MetipranololMetipranolol may increase the hypotensive activities of Efonidipine.Approved
MetolazoneMetolazone may increase the hypotensive activities of Efonidipine.Approved
MetoprololMetoprolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
MetyrosineEfonidipine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Efonidipine.Experimental
MibefradilMibefradil may increase the hypotensive activities of Efonidipine.Investigational, Withdrawn
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Efonidipine.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Efonidipine.Approved, Investigational, Vet Approved
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Efonidipine.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Efonidipine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Efonidipine.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Efonidipine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Efonidipine.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Efonidipine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Efonidipine.Approved, Investigational
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Efonidipine.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Efonidipine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Efonidipine.Approved, Investigational
MuzolimineEfonidipine may increase the hypotensive activities of Muzolimine.Experimental
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Efonidipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Efonidipine is combined with Nabilone.Approved, Investigational
NadololNadolol may increase the hypotensive activities of Efonidipine.Approved
NafcillinThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Efonidipine.Approved
NaftopidilEfonidipine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Efonidipine.Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Efonidipine.Approved
NebivololNebivolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
NefazodoneThe risk or severity of hypotension can be increased when Nefazodone is combined with Efonidipine.Approved, Withdrawn
NesiritideThe risk or severity of adverse effects can be increased when Efonidipine is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Efonidipine.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Efonidipine.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Efonidipine.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Efonidipine.Experimental
NicorandilNicorandil may increase the hypotensive activities of Efonidipine.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Nifedipine.Approved
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Efonidipine.Experimental
NiguldipineEfonidipine may increase the hypotensive activities of Niguldipine.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Efonidipine.Investigational
NilvadipineNilvadipine may increase the hypotensive activities of Efonidipine.Approved, Investigational
NimodipineNimodipine may increase the hypotensive activities of Efonidipine.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Efonidipine.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Efonidipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Efonidipine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Efonidipine is combined with Nitroglycerin.Approved, Investigational
NitroprussideEfonidipine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Efonidipine is combined with Nitrous acid.Approved, Investigational
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Efonidipine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Efonidipine.Approved, Illicit
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Efonidipine.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Efonidipine.Approved, Vet Approved
ObinutuzumabEfonidipine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Efonidipine.Withdrawn
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Efonidipine.Approved, Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Efonidipine.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Efonidipine.Investigational
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Efonidipine.Experimental
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Efonidipine.Approved, Illicit
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Efonidipine.Approved
OxprenololOxprenolol may increase the hypotensive activities of Efonidipine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Efonidipine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Efonidipine.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Efonidipine is combined with Paclitaxel.Approved, Vet Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Efonidipine.Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Efonidipine.Approved
PapaverineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Papaverine.Approved, Investigational
PargylinePargyline may increase the hypotensive activities of Efonidipine.Approved
PenbutololPenbutolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Efonidipine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Efonidipine.Approved, Vet Approved
PentobarbitalThe metabolism of Efonidipine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Efonidipine.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Efonidipine.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Efonidipine.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilPerindopril may increase the hypotensive activities of Efonidipine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Efonidipine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Efonidipine.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Efonidipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Efonidipine.Withdrawn
PhenobarbitalThe metabolism of Efonidipine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Efonidipine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Efonidipine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Efonidipine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Efonidipine.Approved
PinacidilPinacidil may increase the hypotensive activities of Efonidipine.Approved
PindololPindolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Efonidipine is combined with Pipamperone.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Efonidipine.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Efonidipine.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Efonidipine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Efonidipine.Withdrawn
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Efonidipine.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Efonidipine.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Efonidipine.Approved
PosaconazoleThe therapeutic efficacy of Posaconazole can be increased when used in combination with Efonidipine.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Efonidipine is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Efonidipine.Approved
PrazosinPrazosin may increase the hypotensive activities of Efonidipine.Approved
PrimidoneThe metabolism of Efonidipine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineProcaine may increase the hypotensive activities of Efonidipine.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Efonidipine.Approved, Investigational
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Efonidipine.Approved, Vet Approved
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Efonidipine.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Efonidipine.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Efonidipine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Efonidipine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Efonidipine.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Quetiapine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Efonidipine.Approved, Investigational
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Efonidipine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Efonidipine.Approved
RacepinephrineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Efonidipine.Approved
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Efonidipine.Experimental
RamiprilRamipril may increase the hypotensive activities of Efonidipine.Approved
RasagilineRasagiline may increase the hypotensive activities of Efonidipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Efonidipine.Approved
RemikirenRemikiren may increase the hypotensive activities of Efonidipine.Approved
RescinnamineEfonidipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Efonidipine.Approved, Investigational
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Efonidipine.Approved, Investigational
RifampicinThe risk or severity of hypotension can be increased when Rifampicin is combined with Efonidipine.Approved
RifapentineThe risk or severity of hypotension can be increased when Rifapentine is combined with Efonidipine.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Efonidipine.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Efonidipine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Efonidipine.Approved
RiociguatEfonidipine may increase the hypotensive activities of Riociguat.Approved
RisperidoneEfonidipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabEfonidipine may increase the hypotensive activities of Rituximab.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Efonidipine is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Ropivacaine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Efonidipine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Efonidipine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Efonidipine.Withdrawn
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Efonidipine.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Efonidipine.Approved, Investigational, Vet Approved
SaprisartanSaprisartan may increase the hypotensive activities of Efonidipine.Experimental
SecobarbitalThe metabolism of Efonidipine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Efonidipine.Approved, Investigational, Vet Approved
SelexipagEfonidipine may increase the hypotensive activities of Selexipag.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Efonidipine.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Efonidipine is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Efonidipine.Approved, Investigational
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Efonidipine.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Efonidipine.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Efonidipine.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Efonidipine.Approved, Investigational
SitaxentanEfonidipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium phosphate, monobasicEfonidipine may increase the nephrotoxic activities of Sodium phosphate.Approved
SotalolThe risk or severity of adverse effects can be increased when Efonidipine is combined with Sotalol.Approved
SpiraprilSpirapril may increase the hypotensive activities of Efonidipine.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Efonidipine is combined with Spironolactone.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Efonidipine is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Efonidipine.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Efonidipine.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Efonidipine.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Efonidipine.Approved, Investigational
TalinololEfonidipine may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Efonidipine.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Efonidipine.Approved
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Efonidipine.Approved, Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Efonidipine.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Efonidipine.Experimental, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Efonidipine.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Efonidipine.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Efonidipine.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Efonidipine.Experimental
TerlipressinTerlipressin may increase the hypotensive activities of Efonidipine.Approved, Investigational
TetrahydropalmatineEfonidipine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Efonidipine is combined with Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineEfonidipine may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineTheophylline may increase the antihypertensive activities of Efonidipine.Approved
ThiamylalThe metabolism of Efonidipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Efonidipine can be increased when combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Efonidipine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Thioridazine.Approved, Withdrawn
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Efonidipine.Approved
TiboloneTibolone may increase the hypotensive activities of Efonidipine.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of Efonidipine.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Efonidipine.Experimental
TimololTimolol may increase the hypotensive activities of Efonidipine.Approved
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Efonidipine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Tizanidine.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Efonidipine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Efonidipine is combined with Tolcapone.Approved, Withdrawn
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Efonidipine.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Efonidipine.Approved, Investigational, Vet Approved
TolonidineEfonidipine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Efonidipine.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Efonidipine.Approved
TorasemideTorasemide may increase the hypotensive activities of Efonidipine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Efonidipine.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Efonidipine.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Efonidipine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Efonidipine.Approved
TrazodoneThe risk or severity of hypotension can be increased when Trazodone is combined with Efonidipine.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Efonidipine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Efonidipine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Efonidipine is combined with Triamterene.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Efonidipine.Approved, Vet Approved
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Efonidipine.Approved, Investigational
TrimazosinTrimazosin may increase the hypotensive activities of Efonidipine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Efonidipine.Approved, Investigational
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Efonidipine.Approved, Investigational
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Efonidipine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Efonidipine.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Efonidipine.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Efonidipine.Investigational
ValsartanValsartan may increase the hypotensive activities of Efonidipine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Efonidipine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Efonidipine is combined with Verapamil.Approved
VincamineEfonidipine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineEfonidipine may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe therapeutic efficacy of Voriconazole can be increased when used in combination with Efonidipine.Approved, Investigational
WortmanninThe therapeutic efficacy of Wortmannin can be increased when used in combination with Efonidipine.Experimental
XipamideEfonidipine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Efonidipine.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Efonidipine.Approved, Investigational, Vet Approved
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Efonidipine.Approved
ZofenoprilEfonidipine may increase the hypotensive activities of Zofenopril.Experimental
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Efonidipine.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Tanaka H, Shigenobu K: Efonidipine hydrochloride: a dual blocker of L- and T-type ca(2+) channels. Cardiovasc Drug Rev. 2002 Winter;20(1):81-92. [PubMed:12070536]
  2. Nakano N, Ishimitsu T, Takahashi T, Inada H, Okamura A, Ohba S, Matsuoka H: Effects of efonidipine, an L- and T-type calcium channel blocker, on the renin-angiotensin-aldosterone system in chronic hemodialysis patients. Int Heart J. 2010 May;51(3):188-92. [PubMed:20558909]
  3. Hasegawa K, Wakino S, Kanda T, Yoshioka K, Tatematsu S, Homma K, Takamatsu I, Sugano N, Hayashi K: Divergent action of calcium channel blockers on ATP-binding cassette protein expression. J Cardiovasc Pharmacol. 2005 Dec;46(6):787-93. [PubMed:16306803]
  4. Hayashi K, Homma K, Wakino S, Tokuyama H, Sugano N, Saruta T, Itoh H: T-type Ca channel blockade as a determinant of kidney protection. Keio J Med. 2010;59(3):84-95. [PubMed:20881449]
  5. Effects of efonidipine, an L- and T-Type dual calcium channel blocker, on heart rate and blood pressure in patients with mild to severe hypertension: an uncontrolled, open-label pilot study☆ [Link]
  6. Pharmaceutical Substances, 5th Edition, 2009 [Link]
  7. Pharmacokinetic Interaction between Warfarin and Efonidipine in Rats [Link]
  8. Clinical Efficacy of Efonidipine Hydrochloride, a T-type Calcium Channel Inhibitor, on Sympathetic Activities Examination Using Spectral Analysis of Heart Rate/Blood Pressure Variabilities and 123I-Metaiodobenzylguanidine Myocardial Scintigraphy [Link]
  9. DORSET CARDIOLOGY WORKING GROUP GUIDELINE FOR CALCIUM CHANNEL BLOCKERS IN HYPERTENSION [Link]
  10. Relationship between Lipophilicities of 1,4-Dihydropyridine Derivatives and Pharmacokinetic Interaction Strengths with Grapefruit Juice [Link]
  11. Effect of an L- and T-Type Calcium Channel Blocker on 24-Hour Systolic Blood Pressure and Heart Rate in Hypertensive Patients [Link]
  12. Efonidipine [Link]
  13. Drug profile: Efonidipine [Link]
  14. Studies on the Metabolic Fate of NZ-105. (I). Absorption, Distribution, Metabolism and Excretion after a Single Administration to Rats. [Link]
  15. Efonidipine [Link]
  16. CHEMICAL IDENTIFICATION [Link]
External Links
PubChem Compound
119171
PubChem Substance
310265139
ChemSpider
106463
ChEBI
135859
ChEMBL
CHEMBL2074922
Wikipedia
Efonidipine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableRecruitingBasic ScienceEndothelium, Vascular1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
boiling point (°C)746.9±60.0 °C https://www.chemsrc.com/en/searchResult/Efonidipine%20hydrochloride%20ethanolate/
water solubilitypoorly solublehttps://www.ncbi.nlm.nih.gov/pubmed/27553261
Predicted Properties
PropertyValueSource
Water Solubility0.000248 mg/mLALOGPS
logP5.35ALOGPS
logP5.44ChemAxon
logS-6.4ALOGPS
pKa (Strongest Acidic)19.49ChemAxon
pKa (Strongest Basic)2.33ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area120.24 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity175.4 m3·mol-1ChemAxon
Polarizability64.96 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylbenzamines. These are aromatic compounds consisting of a benzyl group that is N-linked to a benzamine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylmethylamines
Direct Parent
Phenylbenzamines
Alternative Parents
Dihydropyridinecarboxylic acids and derivatives / Nitrobenzenes / Aniline and substituted anilines / Benzylamines / Dialkylarylamines / Nitroaromatic compounds / Phosphonic acid diesters / Aralkylamines / Phosphonic acid esters / Vinylogous amides
show 15 more
Substituents
Phenylbenzamine / Dihydropyridinecarboxylic acid derivative / Nitrobenzene / Benzylamine / Nitroaromatic compound / Tertiary aliphatic/aromatic amine / Dialkylarylamine / Aniline or substituted anilines / Dihydropyridine / Phosphonic acid diester
show 36 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1I
Uniprot ID
Q9P0X4
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1I
Molecular Weight
245100.8 Da
References
  1. Tanaka H, Shigenobu K: Efonidipine hydrochloride: a dual blocker of L- and T-type ca(2+) channels. Cardiovasc Drug Rev. 2002 Winter;20(1):81-92. [PubMed:12070536]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
References
  1. Tanaka H, Shigenobu K: Efonidipine hydrochloride: a dual blocker of L- and T-type ca(2+) channels. Cardiovasc Drug Rev. 2002 Winter;20(1):81-92. [PubMed:12070536]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Pharmacokinetic Interaction between Warfarin and Efonidipine in Rats [Link]

Drug created on October 23, 2015 10:29 / Updated on July 02, 2018 20:43